Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNS-101 · 1 trial · 22 indications
Incidence, nature and severity of treatment-related adverse events
Incidence and nature of dose-limiting toxicities
Measured by RECIST 1.1 and iRECIST
| Arm | Type | Description |
|---|---|---|
| Part A - SNS-101 Monotherapy Dose Escalation and Dose Expansion | EXPERIMENTAL | SNS-101 IV alone every 21 days. Patients initially enroll in dose escalation cohorts. |
| Part B - SNS-101 in combination with cemiplimab and Dose Expansion | EXPERIMENTAL | SNS-101 IV and cemiplimab IV every 21 days. Patients initially enroll in dose escalation cohorts. |
| Part C - Cohort Expansion - SNS-101 alone or in combination with cemiplimab | EXPERIMENTAL | SNS-101 IV alone or in combination with cemplimab IV every 21 days at the RP2D. Following completion of the Phase 1 Parts A and B portions of the study, the Phase 2, Part C portion was never initiated. No participants were enrolled in Part C. |
| Name | Type | Description |
|---|---|---|
| SNS-101 (anti-VISTA) | DRUG | SNS-101 IV every 21 days. |
| Cemiplimab | DRUG | Cemiplimab IV every 21 days. |
Key Inclusion Criteria: * Histologically or cytologically documented locally advanced, unresectable or metastatic solid tumor. * Having received and failed or was intolerant to standard of care for advanced disease or not eligible for standard of care therapy with the following tumor types for pati...
SNS-101 is an investigational small molecule being studied for the treatment of advanced solid tumors in adults, including head and neck cancer, breast cancer, colon cancer, pancreatic cancer, gastric cancer, esophageal cancer, prostate cancer, uterine cancer, cervix cancer, ovarian cancer, kidney cancer, bladder cancer, thyroid cancer, melanoma, sarcoma, non-small cell lung cancer, and Merkel cell carcinoma.
SNS-101 is an anti-VISTA agent, meaning it targets VISTA (V-domain Ig suppressor of T cell activation), an immune checkpoint protein. By targeting VISTA, SNS-101 is designed to modulate the immune system's response to tumors, potentially enhancing the body's ability to fight cancer cells.
SNS-101 is being developed by Sensei Biotherapeutics, Inc., a biopharmaceutical company. The company is listed on the stock exchange under the ticker symbol FTH.
SNS-101 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is evaluating the safety, tolerability, and preliminary efficacy of SNS-101 as a monotherapy and in combination with cemiplimab.
SNS-101 is being studied in a Phase 1 clinical trial with the identifier NCT05864144. This trial is evaluating SNS-101 as a monotherapy and in combination with cemiplimab in patients with advanced solid tumors. The study has an enrollment of 98 participants and is being conducted in the United States.
SNS-101 is an anti-VISTA agent, meaning it is a drug that targets the VISTA protein. While SNS-101 is the specific drug name, it is often referred to as an anti-VISTA therapy in the context of its mechanism of action. The drug is being investigated for its potential to treat various advanced solid tumors.